36968-94-2 Usage
Uses
Used in Pharmaceutical Research and Development:
4-(4-Chlorobenzyl)piperidine hydrochloride is used as a key intermediate in the synthesis of various drugs and biologically active compounds. Its presence in the molecular structure can impart specific pharmacological properties, making it a valuable component in the development of new medications.
Used in Organic Synthesis:
As a building block in organic synthesis, 4-(4-Chlorobenzyl)piperidine hydrochloride is utilized in the preparation of a wide range of organic compounds. Its reactivity and functional groups allow for various chemical reactions, enabling the creation of diverse molecules with potential applications in different industries.
Used in Drug Production:
4-(4-Chlorobenzyl)piperidine hydrochloride is employed as an intermediate in the production of various drugs. Its incorporation into the molecular structure of these drugs can enhance their efficacy, selectivity, and pharmacokinetic properties, ultimately contributing to improved therapeutic outcomes for patients.
Used in Medical Treatments:
4-(4-Chlorobenzyl)piperidine hydrochloride has been studied for its potential pharmacological properties, and it may have applications in the treatment of various medical conditions. Its specific interactions with biological targets can lead to the development of novel therapeutic agents for the management of different diseases and disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 36968-94-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,9,6 and 8 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 36968-94:
(7*3)+(6*6)+(5*9)+(4*6)+(3*8)+(2*9)+(1*4)=172
172 % 10 = 2
So 36968-94-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H16ClN.ClH/c13-12-3-1-10(2-4-12)9-11-5-7-14-8-6-11;/h1-4,11,14H,5-9H2;1H
36968-94-2Relevant academic research and scientific papers
20-HETE FORMATION INHIBITORS
-
Paragraph 0470-0473; 0474; 0475, (2020/08/23)
This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.
Subtype-selective NMDA receptor ligands and the use thereof
-
, (2008/06/13)
The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neuro-degenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
